Early evidence of disease activity during fingolimod predicts medium-term inefficacy in relapsing-remitting multiple sclerosis — Laura Ferrè (2020) | RDL Network
Early evidence of disease activity during fingolimod predicts medium-term inefficacy in relapsing-remitting multiple sclerosis
Article 2020 en
Authors
LF
Laura Ferrè
AM
Andrea Mogavero
FC
Ferdinando Clarelli
Abstract
1 min read
FTY effectiveness persists at medium-term follow-up; a close monitoring during the first year of treatment is warranted to early identify non-responders requiring treatment optimization.
Discussion(0)
No comments yet. Be the first to comment.